Recent developments in gene-directed enzyme prodrug therapy (GDEPT) for cancer.
Curr Opin Mol Ther
; 1(4): 480-6, 1999 Aug.
Article
in En
| MEDLINE
| ID: mdl-11713763
ABSTRACT
Gene-directed enzyme prodrug therapy (GDEPT) is a promising two-step treatment for solid malignant tumors. In the first step, the gene for a foreign enzyme is administered and directed to the tumor, where it may be expressed using specific transcriptional elements. In the second step, prodrugs are administered and activated by the foreign enzyme expressed at the tumor. This review focuses on the progress from the end of 1997 to date. Important issues, such as viral and non-viral vectors, new enzyme/prodrug systems, new strategies, advances in the understanding of the bystander effects, the comparison of different systems used in GDEPT and clinical trials are outlined.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Prodrugs
/
Genetic Therapy
/
Enzymes
/
Neoplasms
Type of study:
Prognostic_studies
Language:
En
Journal:
Curr Opin Mol Ther
Journal subject:
BIOLOGIA MOLECULAR
/
TERAPEUTICA
Year:
1999
Document type:
Article
Affiliation country:
United kingdom
Publication country:
ENGLAND
/
ESCOCIA
/
GB
/
GREAT BRITAIN
/
INGLATERRA
/
REINO UNIDO
/
SCOTLAND
/
UK
/
UNITED KINGDOM